Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients (AERODUO-2)

17 novembre 2026 aggiornato da: AeroRx Therapeutics Inc.

Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered Via Nebulization in Participants With Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)

This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).

Panoramica dello studio

Descrizione dettagliata

Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for patients with chronic obstructive pulmonary disease (COPD). Although there are currently multiple LABA+LAMA combination bronchodilators available in metered dose inhalers (MDIs), dry powder inhalers (DPI), and soft mist inhalers (SMI), a significant percentage of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers.

Nebulized delivery provides an effective alternative where disease management is sub optimal. To date there are no approved LABA+LAMA combinations available by nebulization.

AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) for delivery in a general purpose nebulizer device. A phase 2a, single-dose, dose-ranging study of AERO-007 has been completed in participants with COPD at two dose levels (100/50 µg and 200/100 µg). AERO-007 at both low and high doses was well tolerated with robust, clinically meaningful and statistically significant bronchodilation with rapid onset of action that was sustained for 24 hours.

The objective of this phase 2b study is to determine the optimal doses of the monotherapy components of AERO-007 and to assess the safety, PK and bronchodilation profile of AERO-007 following 14 days of dosing in participants with COPD.

Tipo di studio

Interventistico

Iscrizione (Stimato)

64

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • London, Regno Unito
        • Reclutamento
        • Parexel
      • Manchester, Regno Unito
        • Reclutamento
        • Medicines Evaluation Unit

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 40 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Male or female aged 40 to 75 years, inclusive, at the time of informed consent

  • Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1

  • Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of albuterol via MDI with a spacer) at Screening Visit 2 demonstrating the following:

    • FEV1 > 40 and < 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values)
    • FEV1/forced vital capacity (FVC) ratio < 0.70
    • ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of albuterol
  • Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit

  • Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)

  • Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines

  • Female participants of childbearing potential must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective birth control from the time of informed consent and for 30 days following the last administered dose

  • Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit

  • Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose

  • Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose

  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
  • Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) type 1 and/or 2 antibodies at Screening Visit 1
  • Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
  • Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or systemic corticosteroid treatment within 6 months prior to Screening Visit 1
  • Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
  • Prior lung volume reduction surgery or history of chest/lung irradiation
  • Daily oxygen therapy for > 12 hours per day
  • Body mass index >35 kg/m2
  • Abnormal and clinically significant 12-lead ECG findings at Screening Visit 1
  • Current or recent history of medical conditions that are contraindicated for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
  • Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
  • Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
  • Donation of 450 mL of blood within 8 weeks of Screening Visit 1
  • Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
  • History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
  • History of intolerance or hypersensitivity to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
  • Participation in another investigational drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
  • History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione fattoriale
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo

Double-blind

Sperimentale: Aero-001 dose bassa

Double-blind

Sperimentale: Aero-001 Dose alta

Double-blind

Sperimentale: Aero-002 Dose bassa

Double-blind

Sperimentale: Aero-002 Dose alta

Double-blind

Sperimentale: AERO-001 medium dose

Double-blind

Sperimentale: AERO-002 medium dose

Double-blind

Sperimentale: AERO-007

Double-blind

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Bronchodilation - FEV1
Lasso di tempo: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Bronchodilation - FEV AUC
Lasso di tempo: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Bronchodilation - Peak FEV1
Lasso di tempo: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Bronchodilation - time to onset of FEV1 >100mL
Lasso di tempo: Change in FEV1 >100mL from pre-dose on Days 1 and 14
Change in FEV1 >100mL from pre-dose on Days 1 and 14

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pharmacokinetics - Cmax
Lasso di tempo: 0-24 hours on Days 1 and 14

Cmax (maximum plasma concentration)

0-24 hours on Days 1 and 14
Pharmacokinetics - AUC
Lasso di tempo: AUC(0-6 hours) on Days 1 and 14

AUC (area under the plasma concentration)

AUC(0-6 hours) on Days 1 and 14
Pharmacokinetics - Tmax
Lasso di tempo: Tmax on Days 1 and 14

Tmax (time to maximum concentration)

Tmax on Days 1 and 14
Treatment-emergent adverse events (TEAEs)
Lasso di tempo: Up to approximately Day 14

Number of participants with TEAEs

Up to approximately Day 14
Blood Pressure
Lasso di tempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in Blood Pressure

Up to approximately Day 14
Heart Rate
Lasso di tempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in Heart Rate

Up to approximately Day 14
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Lasso di tempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in QTcF

Up to approximately Day 14
Clinical laboratory - Hematology
Lasso di tempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in hematology parameters

Up to approximately Day 14
Clinical laboratory - Blood Chemistry
Lasso di tempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in blood chemistry parameters

Up to approximately Day 14

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 novembre 2026

Completamento primario (Stimato)

1 giugno 2027

Completamento dello studio (Stimato)

1 settembre 2027

Date di iscrizione allo studio

Primo inviato

14 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

19 ottobre 2026

Primo Inserito (Effettivo)

26 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi